Orchard HSC-GT Programs
Wiskott-Aldrich Syndrome, MPS-IH, Beta-Thalassemia
Phase 1/2Active
Key Facts
Indication
Wiskott-Aldrich Syndrome, MPS-IH, Beta-Thalassemia
Phase
Phase 1/2
Status
Active
Company
About Kyowa Hakko Kirin
Kyowa Kirin is a publicly traded, global specialty pharma leader with deep roots in Japanese innovation, strategically focused on high-need therapeutic areas including bone & mineral disorders, hematologic malignancies, and rare diseases. Its success is built on proprietary technology platforms like POTELLIGENT® for enhanced antibody therapeutics and the Orchard Therapeutics acquisition for hematopoietic stem cell gene therapy. The company's strategy combines internal R&D excellence with strategic business development to build a sustainable pipeline of transformative medicines, aiming to deliver its 'Vision 2030' of creating life-changing value for patients worldwide.
View full company profile